Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential
The goal of this clinical research study is to learn if intensive chemotherapy (hyper-CVAD
therapy) given in combination with liposomal vincristine (Marqibo), in addition to rituximab
for patients who are CD20 positive and/or imatinib, dasatinib, or ruxolitinib for patients
with the Philadelphia (Ph) chromosome, can help to control ALL or lymphoblastic lymphoma. The
safety of this treatment will also be studied. CD20 is a protein "marker" that is found in
leukemia or lymphoma cells.
This is an investigational study. Liposomal vincristine is FDA approved for the treatment of
patients with CLL who have relapsed at least 2 times. All of the other study drugs used in
this study are FDA approved and commercially available. The combination of liposomal
vincristine with the other study drugs is also being used in research only.
Up to 65 patients will take part in this study. All will be enrolled at MD Anderson.